2023-2024 discussions with big pharmasFair to assume that if there va are no delays, TLT will wait to be officially granted for the FDA Breakthrough Therapy designation before sending official communication documents (portfolio, profile) to all big pharmas targeted. That would be counterproductive to have already sent this and having to resend an updated version indicating that they now have received FDA Breakthrough Therapy designation, for example.
Then, they'll await response from these big pharmas, as they come, and analyze each of them, with back and forth discussions/negociations.
That how it works in the industry. On the NASDAQ, there is special forms that have to be filled in by Boards where you see all this documented. I posted on couple of occasions such forms.
Schedule 14D-9 is a filing with the Securities and Exchange Commission (SEC) made by a target company in response to a tender offer made by an interested party.